Chameleon BioSurfaces was a provider of sophisticated surface design technology to medical device companies. Chameleon worked closely with customers to design and produce unique solutions to specific device challenges and opportunities.
It was the leading developer of advanced polymer coatings for implantable medical devices. The technology utilized novel electrically conductive polymer coatings for improved biocompatibility, conformal coverage, electrical performance, and drug release.
Proprietary polymers imparted such features as low thrombogenicity, wetability, biocompatibility and drug-elution. Surfaces were designed so that drugs had a desired elution profile over time or were retained and presented at the device surface.
Midven achieved a profitable exit when Chameleon BioSurfaces was acquired by Biotectix LLC in March 2011.